4
Changes in Ownership
Dyne Therapeutics, Inc. Filed Acc 0000950170-24-030484
Chief Business Officer sold 109,601 shares at an average $26.11 ($2,861,373)
- Chief Business Officer acquired 107,825 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| McNeill Jonathan Chief Business Officer | 2024-03-08 | Option exercise 10b5-1 | +86,159 | $5.54 | $477,321 | 227,343 | D |
| McNeill Jonathan Chief Business Officer | 2024-03-08 | Option exercise 10b5-1 | +3,841 | $5.54 | $21,279 | 231,184 | D |
| McNeill Jonathan Chief Business Officer | 2024-03-08 | Sale 10b5-1 | −34,663 | $25.46 | $882,520 | 196,521 | D |
| McNeill Jonathan Chief Business Officer | 2024-03-08 | Sale 10b5-1 | −54,648 | $26.72 | $1,460,195 | 141,873 | D |
| McNeill Jonathan Chief Business Officer | 2024-03-08 | Sale 10b5-1 | −689 | $27.31 | $18,817 | 141,184 | D |
| McNeill Jonathan Chief Business Officer | 2024-03-11 | Option exercise 10b5-1 | +17,825 | $5.54 | $98,751 | 159,009 | D |
| McNeill Jonathan Chief Business Officer | 2024-03-11 | Sale 10b5-1 | −17,825 | $25.48 | $454,181 | 141,184 | D |
| McNeill Jonathan Chief Business Officer | 2024-03-11 | Sale 10b5-1 | −1,776 | $25.71 | $45,661 | 139,408 | D |
| Derivatives | |||||||
| McNeill Jonathan Chief Business Officer | 2024-03-08 | Option exercise · Stock option (right to buy) 10b5-1 | −86,159 | 12,309 | D | ||
| McNeill Jonathan Chief Business Officer | 2024-03-08 | Option exercise · Stock option (right to buy) 10b5-1 | −3,841 | D | |||
| McNeill Jonathan Chief Business Officer | 2024-03-11 | Option exercise · Stock option (right to buy) 10b5-1 | −17,825 | 0 | D | ||
| Open-market sales · 109,601 sh · avg $26.11 · $2,861,373 | |||||||
Loading xslF345X05/ownership.xml…